{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T14:59:15Z","timestamp":1768402755985,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiologie"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00117-025-01541-y","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T13:33:55Z","timestamp":1764941635000},"page":"59-66","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bildgebung neurologischer Nebenwirkungen unter Immuntherapien","Imaging of neurological adverse events associated with immunotherapies"],"prefix":"10.1007","volume":"66","author":[{"given":"Timotheus Josef","family":"Neumann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Magdalena","family":"Baz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena Nicola Charlotte","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynep","family":"Bendella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Clauberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Radbruch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Katrin","family":"Pr\u00f6bstel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Bischof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"M\u00f6hn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara Daria","family":"Wichtmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"4","key":"1541_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll\u00a0DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252\u2013264 (https:\/\/www.nature.com\/articles\/nrc3239. Accessed May\u00a023, 2025)","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1541_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/imr.12519","volume":"276","author":"LP Andrews","year":"2017","unstructured":"Andrews\u00a0LP, Marciscano\u00a0AE, Drake\u00a0CG et\u00a0al (2017) LAG3 (CD223) as a\u00a0cancer immunotherapy target. Immunol Rev 276(1):80\u201396. https:\/\/doi.org\/10.1111\/imr.12519","journal-title":"Immunol Rev"},{"issue":"2","key":"1541_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow\u00a0MA, Sidlow\u00a0R, Hellmann\u00a0MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N\u00a0Engl J Med 378(2):158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"1541_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002842","author":"M Kalos","year":"2011","unstructured":"Kalos\u00a0M, Levine\u00a0BL, Porter\u00a0DL et\u00a0al (2011) T cells with chimeric antigen receptors have potent Antitumor effects and Can establish memory in patients with advanced leukemia. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.3002842","journal-title":"Sci Transl Med"},{"key":"1541_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40364-025-00736-8","volume":"13","author":"Q Huang","year":"2025","unstructured":"Huang\u00a0Q, Zhu\u00a0X, Zhang\u00a0Y (2025) Advances in engineered T\u00a0cell immunotherapy for autoimmune and other non-oncological diseases. Biomark Res 13:23 (https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC11792665\/. Accessed August\u00a029, 2025)","journal-title":"Biomark Res"},{"issue":"2","key":"1541_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.bbadis.2010.07.008","volume":"1812","author":"EML Chastain","year":"2011","unstructured":"Chastain\u00a0EML, Duncan\u00a0DS, Rodgers\u00a0JM et\u00a0al (2011) The role of antigen presenting cells in multiple sclerosis. Biochim Biophys Acta BBA Mol Basis Dis 1812(2):265\u2013274 (https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443910001456. Accessed May\u00a027, 2025)","journal-title":"Biochim Biophys Acta BBA Mol Basis Dis"},{"issue":"9","key":"1541_CR7","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nri3265","volume":"12","author":"RM Ransohoff","year":"2012","unstructured":"Ransohoff\u00a0RM, Engelhardt\u00a0B (2012) The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol 12(9):623\u2013635 (https:\/\/www.nature.com\/articles\/nri3265. Accessed May\u00a027, 2025)","journal-title":"Nat Rev Immunol"},{"key":"1541_CR8","doi-asserted-by":"publisher","first-page":"774170","DOI":"10.3389\/fphar.2022.774170\/full","volume":"13","author":"V Albarr\u00e1n","year":"2022","unstructured":"Albarr\u00e1n\u00a0V, Chamorro\u00a0J, Rosero\u00a0DI et\u00a0al (2022) Neurologic toxicity of immune checkpoint inhibitors: a\u00a0review of literature. Front Pharmacol 13:774170. https:\/\/doi.org\/10.3389\/fphar.2022.774170\/full","journal-title":"Front Pharmacol"},{"issue":"12","key":"1541_CR9","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang\u00a0DY, Salem\u00a0J\u2011E, Cohen\u00a0JV et\u00a0al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a\u00a0systematic review and meta-analysis. JAMA Oncol 4(12):1721. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"issue":"12","key":"1541_CR10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.it.2012.07.004","volume":"33","author":"B Engelhardt","year":"2012","unstructured":"Engelhardt\u00a0B, Ransohoff\u00a0RM (2012) Capture, crawl, cross: the T\u00a0cell code to breach the blood-brain barriers. Trends Immunol 33(12):579\u2013589 (https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471490612001263. Accessed May\u00a027, 2025)","journal-title":"Trends Immunol"},{"issue":"4","key":"1541_CR11","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","volume":"25","author":"N Frey","year":"2019","unstructured":"Frey\u00a0N, Porter\u00a0D (2019) Cytokine release syndrome with chimeric antigen receptor T\u00a0cell therapy. Biol Blood Marrow Transplant 25(4):e123\u2013e127 (ttps:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118315799. Accessed June\u00a012, 2025)","journal-title":"Biol Blood Marrow Transplant"},{"key":"1541_CR12","doi-asserted-by":"crossref","unstructured":"Han MW, Jeong SY, Suh CH et\u00a0al (2024) Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T\u2011cell therapy for hematologic malignancies: systematic review and meta-analysis. Front Neurol 15: (https:\/\/www.frontiersin.org\/journals\/neurology\/articles\/10.3389\/fneur.2024.1392831\/full. Accessed May\u00a023, 2025)","DOI":"10.3389\/fneur.2024.1392831"},{"issue":"6","key":"1541_CR13","doi-asserted-by":"publisher","first-page":"e1576","DOI":"10.1002\/wsbm.1576","volume":"14","author":"T Gu","year":"2022","unstructured":"Gu\u00a0T, Hu\u00a0K, Si\u00a0X et\u00a0al (2022) Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR\u2011T treatment. Wires Mech Dis 14(6):e1576 (https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/wsbm.1576. Accessed May\u00a027, 2025)","journal-title":"Wires Mech Dis"},{"issue":"3","key":"1541_CR14","doi-asserted-by":"publisher","first-page":"fcad169","DOI":"10.1093\/braincomms\/fcad169","volume":"5","author":"A Farina","year":"2023","unstructured":"Farina\u00a0A, Birzu\u00a0C, Elsensohn\u00a0M\u2011H et\u00a0al (2023) Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity. Brain Commun 5(3):fcad169","journal-title":"Brain Commun"},{"issue":"6","key":"1541_CR15","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer\u00a0JR, Abu-Sbeih\u00a0H, Ascierto\u00a0PA et\u00a0al (2021) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. j Immunother Cancer 9(6):e2435","journal-title":"j Immunother Cancer"},{"key":"1541_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","volume":"106","author":"A Moreira","year":"2019","unstructured":"Moreira\u00a0A, Loquai\u00a0C, Pf\u00f6hler\u00a0C et\u00a0al (2019) Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 106:12\u201323 (https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0959804918314035. Accessed June\u00a010, 2025)","journal-title":"Eur J Cancer"},{"issue":"3","key":"1541_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/NRL.0000000000000230","volume":"24","author":"M Xu","year":"2019","unstructured":"Xu\u00a0M, Nie\u00a0Y, Yang\u00a0Y et\u00a0al (2019) Risk of neurological toxicities following the use of different immune checkpoint inhibitor regimens in solid tumors: a\u00a0systematic review and meta-analysis. Neurologist 24(3):75 (https:\/\/journals.lww.com\/theneurologist\/fulltext\/2019\/05000\/risk_of_neurological_toxicities_following_the_use.1.aspx. Accessed June\u00a011, 2025)","journal-title":"Neurologist"},{"issue":"1","key":"1541_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jha2.286","volume":"3","author":"S Sheikh","year":"2022","unstructured":"Sheikh\u00a0S, Mokhtari\u00a0S, Silverman\u00a0JA et\u00a0al (2022) Transverse myelitis after anti-CD19 directed CAR T\u00a0cell therapy for relapsed large B\u00a0cell lymphoma. EJHaem 3(1):223\u2013227","journal-title":"EJHaem."},{"issue":"5","key":"1541_CR19","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.3324\/haematol.2020.259952","volume":"106","author":"R Nair","year":"2021","unstructured":"Nair\u00a0R, Drillet\u00a0G, Lhomme\u00a0F et\u00a0al (2021) Acute leucoencephalomyelopathy and quadriparesis after CAR T\u2011cell therapy. Haematologica 106(5):1504\u20131506","journal-title":"Haematologica"},{"issue":"6","key":"1541_CR20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","volume":"30","author":"M Touat","year":"2017","unstructured":"Touat\u00a0M, Talmasov\u00a0D, Ricard\u00a0D et\u00a0al (2017) Neurological toxicities associated with immune-checkpoint inhibitors. Curr Opin Neurol 30(6):659\u2013668","journal-title":"Curr Opin Neurol"},{"issue":"14","key":"1541_CR21","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.3390\/cancers16142585","volume":"16","author":"C Pozzessere","year":"2024","unstructured":"Pozzessere\u00a0C, Mazini\u00a0B, Omoumi\u00a0P et\u00a0al (2024) Immune-related adverse events induced by immune checkpoint inhibitors and CAR-T\u00a0cell therapy: a\u00a0comprehensive imaging-based review. Cancers 16(14):2585","journal-title":"Cancers"},{"key":"1541_CR22","doi-asserted-by":"publisher","first-page":"100434","DOI":"10.1016\/j.ejro.2022.100434","volume":"9","author":"B Gosangi","year":"2022","unstructured":"Gosangi\u00a0B, McIntosh\u00a0L, Keraliya\u00a0A et\u00a0al (2022) Imaging features of toxicities associated with immune checkpoint inhibitors. Eur J Radiol Open 9:100434","journal-title":"Eur J Radiol Open"},{"issue":"1","key":"1541_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13244-025-01999-3","volume":"16","author":"A Lasocki","year":"2025","unstructured":"Lasocki\u00a0A, Spain\u00a0L (2025) Neuroimaging features of immune-related adverse events due to immune checkpoint inhibitor therapy. Insights Imaging 16(1):120","journal-title":"Insights Imaging"},{"key":"1541_CR24","doi-asserted-by":"crossref","unstructured":"Hassankhani A, Bagley SJ, Dahmoush H et\u00a0al (2025) Role of neuroimaging in cancer-treatment neurotoxicity. Am J Roentgenol","DOI":"10.2214\/AJR.25.33139"},{"issue":"4","key":"1541_CR25","doi-asserted-by":"publisher","first-page":"e200488","DOI":"10.1212\/CPJ.0000000000200488","volume":"15","author":"A Vichare","year":"2025","unstructured":"Vichare\u00a0A, Lee\u00a0JS, Duong\u00a0TQ (2025) Neuroimaging findings of CAR T\u2011cell-associated neurotoxicity: a\u00a0review. Neurol Clin Pract 15(4):e200488","journal-title":"Neurol Clin Pract"},{"issue":"6","key":"1541_CR26","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.2214\/AJR.21.26091","volume":"217","author":"JG Yoon","year":"2021","unstructured":"Yoon\u00a0JG, Smith\u00a0DA, Tirumani\u00a0SH et\u00a0al (2021) CAR T\u2011cell therapy: an update for radiologists. Am J Roentgenol 217(6):1461\u20131474","journal-title":"Am J Roentgenol"},{"issue":"4","key":"1541_CR27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee\u00a0DW, Santomasso\u00a0BD, Locke\u00a0FL et\u00a0al (2019) ASTCT consensus grading for Cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25(4):625\u2013638","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"1541_CR28","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1080\/10428194.2022.2074990","volume":"63","author":"AH Lapidus","year":"2022","unstructured":"Lapidus\u00a0AH, Anderson\u00a0MA, Harrison\u00a0SJ et\u00a0al (2022) Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T\u2011cell therapy. Leuk Lymphoma 63(10):2364\u20132374","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"1541_CR29","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/jon.13138","volume":"33","author":"SN Pinto","year":"2023","unstructured":"Pinto\u00a0SN, C\u2011SJ L, Nelson\u00a0MD et\u00a0al (2023) Neuroimaging of complications arising after CD19 chimeric antigen receptor T\u2011cell therapy: a\u00a0review. J\u00a0Neuroimaging 33(5):703\u2013715","journal-title":"J Neuroimaging"},{"issue":"10","key":"1541_CR30","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1182\/bloodadvances.2023011669","volume":"8","author":"M Mauget","year":"2024","unstructured":"Mauget\u00a0M, Lemercier\u00a0S, Quelven\u00a0Q et\u00a0al (2024) Impact of diagnostic investigations in the management of CAR T\u2011cell-associated neurotoxicity. Blood Adv 8(10):2491\u20132498","journal-title":"Blood Adv"},{"issue":"1","key":"1541_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.rx.2023.09.002","volume":"67","author":"FD Choque-Ch\u00e1vez","year":"2025","unstructured":"Choque-Ch\u00e1vez\u00a0FD, Jare\u00f1o-Badenas\u00a0A, Ben\u00edtez-Ribas\u00a0D et\u00a0al (2025) Evaluation of central nervous system involvement in patients undergoing chimeric antigen receptor-engineered T\u2011cell therapy by magnetic resonance imaging. Radiologia 67(1):91\u201395","journal-title":"Radiologia"},{"issue":"3","key":"1541_CR32","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11547-019-01120-x","volume":"125","author":"F Caranci","year":"2020","unstructured":"Caranci\u00a0F, Leone\u00a0G, Ponsiglione\u00a0A et\u00a0al (2020) Imaging findings in hypophysitis: a\u00a0review. Radiol Med 125(3):319\u2013328","journal-title":"Radiol Med"},{"issue":"3","key":"1541_CR33","doi-asserted-by":"publisher","first-page":"e967","DOI":"10.1212\/NXI.0000000000000967","volume":"8","author":"A Picca","year":"2021","unstructured":"Picca\u00a0A, Berzero\u00a0G, Bihan\u00a0K et\u00a0al (2021) Longitudinally extensive myelitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflammation 8(3):e967","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"Supplement_5","key":"1541_CR34","doi-asserted-by":"publisher","first-page":"v108","DOI":"10.1093\/noajnl\/vdab107","volume":"3","author":"LB Burton","year":"2021","unstructured":"Burton\u00a0LB, Eskian\u00a0M, Guidon\u00a0AC et\u00a0al (2021) A\u00a0review of neurotoxicities associated with immunotherapy and a\u00a0framework for evaluation. Neuro Oncol Adv 3(Supplement_5):v108\u2013v120","journal-title":"Neuro Oncol Adv"},{"issue":"16","key":"1541_CR35","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","volume":"96","author":"A Marini","year":"2021","unstructured":"Marini\u00a0A, Bernardini\u00a0A, Gigli\u00a0GL et\u00a0al (2021) Neurologic adverse events of immune checkpoint inhibitors: a\u00a0systematic review. Neurology 96(16):754\u2013766","journal-title":"Neurology"},{"key":"1541_CR36","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.25.33139","author":"A Hassankhani","year":"2025","unstructured":"Hassankhani\u00a0A, Bagley\u00a0SJ, Dahmoush\u00a0H et\u00a0al (2025) Role of neuroimaging in cancer-treatment neurotoxicity. Am J Roentgenol. https:\/\/doi.org\/10.2214\/ajr.25.33139","journal-title":"Am J Roentgenol"}],"container-title":["Die Radiologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-025-01541-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00117-025-01541-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-025-01541-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T09:19:36Z","timestamp":1768382376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00117-025-01541-y"}},"subtitle":["Immuncheckpoint-Inhibitoren und CAR-T-Zellen","Immune checkpoint inhibitors and CAR-T cells"],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1541"],"URL":"https:\/\/doi.org\/10.1007\/s00117-025-01541-y","relation":{},"ISSN":["2731-7048","2731-7056"],"issn-type":[{"value":"2731-7048","type":"print"},{"value":"2731-7056","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"T.J.\u00a0Neumann, A.M.\u00a0Baz, E.N.C.\u00a0Schmidt, Z.\u00a0Bendella, R.\u00a0Clauberg, A.\u00a0Radbruch, A.-K.\u00a0Pr\u00f6bstel, A.\u00a0Bischof, N.\u00a0M\u00f6hn und B.D.\u00a0Wichtmann geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}